CADL

Over the past six months (April 2026 - October 2026), Candel Therapeutics' stock price increased by 113.53% from September 30, 2025, to September 29, 2026, and by 52.22% over the last year. Recent events include an October 2026 announcement of a presentation at the SITC 2026 Annual Meeting and inducement grants on October 1, 2026. On October 1, 2026, the company published Phase 2a trial data for aglatimagene besadenovec plus valacyclovir in NSCLC, showing prolonged survival and systemic clinical response. On September 30, 2026, new data presented at ASTRO 2026 demonstrated sustained immune remodeling more than two years after aglatimagene besadenovec treatment in localized prostate cancer. Martine Zimmermann was appointed to the Board of Directors on September 10, 2026, and the company made several presentations at investment conferences in September 2026. In August 2026, the stock experienced increases of 10.63% and 4.37% around the 13th and 3rd respectively, alongside a 2.35% decrease around the 26th. In July 2026, the stock price was approximately $9.94 per share.